Clinical Trial Update: Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase I open-label dose-finding study of SGN-35 (brentuximab vedotin) for CD30-positive hematologic malignancies, including non-Hodgkin lymphoma, Hodgkin lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• SGN-35 (brentuximab vedotin) (brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, Non-Hodgkin, Disease, Hodgkin | Phase 1 | Status: COMPLETED